Breaking News
2191 - 2205 of 6609 results
Prev
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
Next
June 15, 2011
Dr. Reddy’s chemical manufacturing facility in Cuernavaca, Mexico has received a four-item Warning Letter from the FDA.
Read More »
June 15, 2011
Bayer HealthCare Pharmaceuticals has submitted an IND application for the TAP compound, BAY 94-9343, triggering a $2 million milestone payment to ImmunoGen.
Read More »
June 15, 2011
Covance is launching Xcellerate, a new methodology designed to help optimize clinical trial performance in order to improve quality, reduce waste and decrease trial timelines.
Read More »
June 15, 2011
Abbott received approval from the FDA for an infant-specific dose of Creon (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
Read More »
June 14, 2011
Array BioPharma will restructure in an effort to extend its financial resources to focus on the development of key clinical programs: ARRY-520, a KSP inhibitor for multiple myeloma, ARRY-614, a p38 / Tie-2 inhibitor for myelodysplastic syndrome, and MEK162, a MEK inhibitor for cancer in co-development with Novartis.
Read More »
June 14, 2011
Arecor and GlaxoSmithKline have entered into a license agreement to develop advanced formulations of vaccines combining Arecor’s formulation technologies with GSK’s proprietary vaccines.
Read More »
June 14, 2011
Roquette has completed its new injectable carbohydrate plant at its Lestrem facility.
Read More »
June 14, 2011
IntraLinks has provided the results of its Global Investigator Site Survey, examining what methods are currently used for clinical trial document exchange and the effectiveness of those methods.
Read More »
June 14, 2011
Sartorius Stedim Biotech (SSB) and Südpack Medica AG have signed an exclusive 10-year agreement for the development, manufacture and supply of polymer plastic films for the biopharmaceutical market.
Read More »
June 13, 2011
Kareus Therapeutics SA has entered a broad strategic alliance with Quintiles to progress the development of two of Kareus’ preclinical programs through clinical trials.
Read More »
June 13, 2011
Merck and Hanwha Chemical Corp. have entered into an exclusive global agreement to develop and commercialize HD203, Hanwha’s biosimilar form of Enbrel. Hanwha, through its Bio Business Unit, and Merck, through a subsidiary, will work to develop and commercialize HD203.
Read More »
June 13, 2011
Valeant Pharmaceuticals International and GlaxoSmithKline have received FDA approval for Potiga (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
Read More »
June 13, 2011
Dr. David Roblin has been appointed to Xceleron’s board of directors in a non-executive capacity and Dr. Stuart Best has been named senior director of operations.
Read More »
2191 - 2205 of 6609 results
Prev
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441
Next



